Seroprevalence, correlates and kinetics of SARS-CoV-2 nucleocapsid IgG antibody in healthcare workers and nonclinical staff at a tertiary hospital: A prevaccine census studyArticle Published on 2022-10-272022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, [키워드] adjusted age Antibody test Asymptomatic category Chemiluminescent assay Comorbidity conducted confidence interval country COVID-19 COVID-19 vaccination determine effective enrolled General population HCW healthcare worker hospital hospital management IgG IgG antibody IgG test implementation increased risk Infection lowest mild symptoms Odds ratio over positive positive PCR test positive SARS-CoV-2 PCR predictor Prevalence preventive measure SAR-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleocapsid sensitivity Seroprevalence Sex staff Symptoms university was performed [DOI] 10.1371/journal.pone.0267619 PMC 바로가기
SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome advanced age analyzed antibodies antibody antibody durability Antibody titer circulation Cohort collected convalescent coronavirus coronavirus disease COVID-19 decrease detectable determine Effectiveness Enrollment exceptional female Health care worker highlight immune responses Increases Infection initial limit Longevity median modeling mounted new SARS-CoV-2 occurred Pandemics participant Participants protection public health crisis Rapid Reinfection risk SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 variant seronegative seropositive seropositive participant severe COVID-19 Sex spike-binding antibodies. stability Steady state vaccination variants of concern viruses [DOI] 10.1128/mbio.01784-22 PMC 바로가기
Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center studyArticle Published on 2022-10-252022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Analysis analyzed Appropriate BMI body mass index cause caused changes in Characteristics city Comorbidities coronavirus coronavirus disease COVID-19 COVID-19 severity cut-off value Dyspnea groups Hospitalization laboratory data LDH management moderate Moderate COVID-19 multiple logistic regression Omicron variant outcome Patient predictor progression renal dysfunction SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sensitivity severe COVID-19 Sex significant difference significantly single center smoking sore throat specificity Symptoms the disease time Treatment treatment regimens two group university vaccination variant Yokohama [DOI] 10.1371/journal.pone.0273134 PMC 바로가기
Clinical characteristics and outcomes of SARS-Cov-2 B.1.1.529 infections in hospitalized patients and multi-surge comparison in LouisianaArticle Published on 2022-10-212022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] Admission age analyzed B.1.1.529 Characteristics clinical Clinical outcome cohort analysis Comorbidity contributed COVID-19 pandemic defined determine diagnoses Diagnosis discharge disease severity Factor Features Fewer patient FIVE higher risk hospital Hospitalization hospitalized patient ICU ICU admission Infection less Mortality omicron one way ANOVA outcome outcomes overall mortality Patient peer positive presenting presenting symptom progressed proportion Protective required risk SARS-CoV-2 SARS-CoV-2 test severe disease Sex subsequent subset Symptom the SARS-CoV-2 the United State vaccination variant Ventilation was performed [DOI] 10.1371/journal.pone.0268853 PMC 바로가기
A prediction model for COVID-19 liver dysfunction in patients with normal hepatic biochemical parametersArticle Published on 2022-10-192022-11-16 Journal: Life Science Alliance [Category] 유전자 메커니즘, [키워드] Accuracy ALT Analysis AST benefit biochemical parameter Biochemical parameters Biomarker clinical variable Cohort Coronavirus disease 2019 COVID-19 COVID-19 patient Critical disease exhibit exhibited high risk identify independent limitation liver dysfunction machine learning model Patient performed predict proteomic serum sample Sex therapeutic strategy [DOI] 10.26508/lsa.202201576 PMC 바로가기
Cross-sectional study for COVID-19-related mortality predictors in a Brazilian state-wide landscape: the role of demographic factors, symptoms and comorbiditiesArticle Published on 2022-10-172022-11-15 Journal: BMJ Open [Category] 진단, [키워드] 95% CI Analysis association cardiac epidemiology Clinical severity Comorbidity COVID-19 COVID-19 pandemic criteria criterion cross-sectional study dataset death demographic characteristics Demographic factors diabete diabetes & diagnosed disease disorder Effects electronic medical record endocrinology Epidemiology evaluate Factor health system healthcare highlight hospitalisation hospitalised ICU implementation increased mortality information Intervention kidney kidney & Kidney disease majority measure mitigate Mortality multicollinearity non-hospitalised non-ICU non-ICU patient occurred Patient patients patients older predictor Prevent public health public health. reverse transcription-PCR secondary outcome selected severity Sex state suffered Symptom Urinary tract urinary tract disorders virus [DOI] 10.1136/bmjopen-2021-056801 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses analysis Analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variantArticle Published on 2022-10-132022-11-15 Journal: International Journal of Epidemiology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] African age antibodies baseline conducted country COVID-19 detectable determine dry cough female Fever groups headache highlight household size indicate individuals infection rate infection rates Kaduna limitation Logistic regression nausea Nigeria omicron participant PCR-confirmed polymerase chain proportion provide public health Reporting SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 seroprevalence sense of taste seropositive status seroprevalence. Serosurvey Sex sore throat Spread state stratified subgroup Symptom tested variant were used [DOI] 10.1093/ije/dyac141 PMC 바로가기
Sex differences in determinants of COVID-19 severe outcomes – findings from the National COVID Cohort Collaborative (N3C)Article Published on 2022-10-122022-11-15 Journal: BMC Infectious Diseases [Category] 바이오마커, [키워드] absolute lymphocyte absolute neutrophil adjusted adjusted odds ratio Admission age Analysis association averaged Biomarker Biomarkers both sexes CCI Charlson Comorbidity Index comorbid condition Comorbidities Comorbidity components COVID COVID-19 COVID-19 severity CRP death death rate defined determinant disease Elevation examined ferritin Health highlight hospital Hospitalized IMV Inflammation inflammatory biomarkers Invasive mechanical ventilation lab value Liver disease Logistic regression LOS lymphocytopenia magnitude male medication men men and women moderate to severe Mortality Myocardial infarction N-terminal neutrophil outcome Patient peptide Platelet Platelets predictor previous study Primary outcome procalcitonin Protein remained renal Research retrospective cohort risk risk factor risk of death secondary outcome Sex Sex difference sex differences. significantly solid tumor with COVID-19 women [DOI] 10.1186/s12879-022-07776-7 PMC 바로가기
Pulmonary Involvement in SARS-CoV-2 Infection Estimates Myocardial Injury RiskArticle Published on 2022-10-112022-11-15 Journal: Medicina [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute respiratory syndrome Admission age Alpha alveolar ambient biochemical biochemical marker Biomarker C reactive protein can be used cardiac injury chest scan Computerized tomography consecutive patients consolidation coronavirus correlated correlation COVID-19 COVID-19 complications COVID-19 patient COVID-19 risk factors CRP CT scan Diastolic blood pressure dysfunction elevated estimate Factor Factors fibrinogen group Hospitalization IL-6 Infection Inflammatory marker Injury interleukin-6 interlobular septal thickening interstitial Involvement lactate dehydrogenase LDH lesion lung Lung disease lung involvement material multisystemic myocardial injury myocardial injury. myocardial involvement Myoglobin Necrosis non-specific NT-proBNP objective Observational cohort study occurred parameters pathology Patient Patient care performed peripheral oxygen saturation Pneumonia pulmonary pulmonary involvement pulmonary lobe radiological Registered respiratory rate respiratory rates Result risk routine SARS-CoV-2 SARS-COV-2 infection Serum ferritin severity Sex significant difference Systolic blood pressure the disease the patient the study group TnI [DOI] 10.3390/medicina58101436 PMC 바로가기